| Half-life | 50 days |
| Tmax | 3 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 96 % |
| Volume of Distribution | 60 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Very long t½; loading dose needed; monitor thyroid & liver. |
Severity: Life-threatening
Adverse Effects:
Pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, corneal deposits, skin discoloration
Contraindications:
Severe thyroid disease
Precautions:
Check TFTs, LFTs, CXR periodically; avoid sun; many drug interactions (CYP inhibitor)